Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated April 14, 2022, reports on share repurchase activities for the period from March 1, 2022, to March 31, 2022. The document serves as a translation of the company's Share Repurchase Report filed with the Kanto Local Finance Bureau under Japanese law.
Key Financial Metrics
The filing focuses exclusively on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Repurchase Program Authorization: Approved by the Board of Directors on October 28, 2021, for a maximum of 35,000,000 shares with a total budget of 100,000,000,000 JPY.
- Program Duration: November 2, 2021, to April 29, 2022.
- Repurchases in Reporting Month: No shares were repurchased during March 2022.
- Cumulative Repurchases (as of March 31, 2022): 22,469,400 shares for a total amount of 74,972,698,800 JPY.
- Program Progress: 64.20% of the authorized share count and 74.97% of the authorized budget have been utilized.
- Treasury Shares Held: 22,645,917 shares as of March 31, 2022, out of 1,582,252,525 total issued shares.
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There were no material changes in share repurchase activity during the reporting month of March 2022 compared to the prior period, as no shares were purchased during this specific month. The cumulative position remains unchanged from the end of February 2022.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or risk factors. It strictly reports the status of the share repurchase resolution. The program is scheduled to conclude on April 29, 2022.
Investor Verification Checklist
- Verify the final repurchase volume and cost upon the program's conclusion on April 29, 2022.
- Confirm the treatment of the 22,645,917 treasury shares (e.g., cancellation vs. retention) in future filings.
- Note that the treasury share count excludes shares held by the ESOP trust account and the BIP trust account.
- Review subsequent filings for operational financial results, as this document contains no P&L or balance sheet data.